Ranked by CareCost Buy-and-Bill Risk Score (25 risk-scored drugs), followed by 3 additional Medicare price-negotiation (IRA) baseline drugs not otherwise on the risk list. Index is a multiple of Medicare ASP (ASP=100).
| Rank | Drug | Median index | Insurers |
|---|---|---|---|
| #1 | Enhertu (J9358) Median 95.2 on ASP=100 (7.3% below acquisition) across 58 insurers. | 95.2 | 58 |
| #2 | Octreotide Acetate Er (J2353) Median 96.6 on ASP=100 (5.9% below acquisition) across 58 insurers. | 96.6 | 58 |
| #3 | Orencia (J0129) Median 97.6 on ASP=100 (5.0% below acquisition) across 58 insurers. | 97.6 | 58 |
| #4 | Lanreotide Acetate (J1930) Median 95.4 on ASP=100 (7.1% below acquisition) across 56 insurers. | 95.4 | 56 |
| #5 | Syfovre (J2781) Median 96.2 on ASP=100 (6.3% below acquisition) across 51 insurers. | 96.2 | 51 |
| #6 | Evenity (J3111) Median 95.7 on ASP=100 (6.8% below acquisition) across 58 insurers. | 95.7 | 58 |
| #7 | Imfinzi (J9173) Median 98.1 on ASP=100 (4.5% below acquisition) across 57 insurers. | 98.1 | 57 |
| #8 | Ocrevus (J2350) Median 97.8 on ASP=100 (4.8% below acquisition) across 58 insurers. | 97.8 | 58 |
| #9 | Prolia (J0897) Median 98.0 on ASP=100 (4.6% below acquisition) across 59 insurers. | 98.0 | 59 |
| #10 | Xolair (J2357) Median 97.7 on ASP=100 (4.9% below acquisition) across 58 insurers. | 97.7 | 58 |
| #11 | Nplate (J2802) Median 95.6 on ASP=100 (6.9% below acquisition) across 55 insurers. | 95.6 | 55 |
| #12 | Opdivo (J9299) Median 98.2 on ASP=100 (4.4% below acquisition) across 58 insurers. | 98.2 | 58 |
| #13 | Kyprolis (J9047) Median 94.5 on ASP=100 (8.0% below acquisition) across 57 insurers. | 94.5 | 57 |
| #14 | Entyvio (J3380) Median 98.8 on ASP=100 (3.8% below acquisition) across 59 insurers. | 98.8 | 59 |
| #15 | Krystexxa (J2507) Median 97.3 on ASP=100 (5.3% below acquisition) across 57 insurers. | 97.3 | 57 |
| #16 | Polivy (J9309) Median 95.6 on ASP=100 (6.9% below acquisition) across 57 insurers. | 95.6 | 57 |
| #17 | Gammagard Liquid (J1569) Median 99.5 on ASP=100 (3.1% below acquisition) across 58 insurers. | 99.5 | 58 |
| #18 | Reblozyl (J0896) Median 98.3 on ASP=100 (4.3% below acquisition) across 57 insurers. | 98.3 | 57 |
| #19 | Darzalex Faspro (J9144) Median 98.6 on ASP=100 (4.0% below acquisition) across 58 insurers. | 98.6 | 58 |
| #20 | Tecentriq (J9022) Median 98.2 on ASP=100 (4.4% below acquisition) across 58 insurers. | 98.2 | 58 |
| #21 | Truxima (Q5115) Median 89.8 on ASP=100 (12.6% below acquisition) across 57 insurers. | 89.8 | 57 |
| #22 | Adcetris (J9042) Median 96.2 on ASP=100 (6.3% below acquisition) across 58 insurers. | 96.2 | 58 |
| #23 | Yervoy (J9228) Median 98.3 on ASP=100 (4.3% below acquisition) across 57 insurers. | 98.3 | 57 |
| #24 | Hizentra (J1559) Median 97.7 on ASP=100 (4.9% below acquisition) across 57 insurers. | 97.7 | 57 |
| #25 | Privigen (J1459) Median 99.1 on ASP=100 (3.5% below acquisition) across 57 insurers. | 99.1 | 57 |
| IRA baseline | Botox (J0585) Median 100.1 on ASP=100 (2.5% below acquisition) across 59 insurers. | 100.1 | 59 |
| IRA baseline | Cimzia (J0717) Median 113.5 on ASP=100 (10.5% above acquisition) across 57 insurers. | 113.5 | 57 |
| IRA baseline | Cosentyx (J3247) Median 99.1 on ASP=100 (3.5% below acquisition) across 50 insurers. | 99.1 | 50 |